SIOLOGICALS a biotechne brand

ELISA PRODUCT INFORMATION & MANUAL

Human Factor V ELISA Kit NBP2-60561

Enzyme-linked Immunosorbent Assay for quantitative detection of Human Factor V. For research use only. Not for diagnostic or therapeutic procedures.

www.novusbio.com - P: 303.730.1950 - P: 888.506.6887 - F: 303.730.1966 - technical@novusbio.com

Novus kits are guaranteed for 6 months from date of receipt

Assay Summary

Step 1. Add 50 μl of Standard or Sample per well. Incubate 2 hours.

Step 2. Wash, then add 50 μl of Biotinylated Antibody per well. Incubate 1 hour.

Step 3. Wash, then add 50 μl of SP Conjugate per well. Incubate 30 minutes.

Step 4. Wash, then add 50 μl of Chromogen Substrate per well. Incubate 10 minutes.

Step 5. Add 50 μ l of Stop Solution per well. Read at 450 nm immediately.

Symbol Key

i

Consult instructions for use.

Assay
<u> </u>
Fe
3
σ
פט
-
Ð

	1	2	3	4	5	6	7	8	9	10	11	12
А												
В												
с												
D												
E												
F												
G												
н												

Human Factor V ELISA Kit

Catalog No. NBP2-60561 Sample insert for reference use only

Introduction

Factor V (FV) is an essential cofactor of the blood coagulation cascade and circulates in plasma as a large single-chain glycoprotein (330 kDa). The deduced amino acid sequence consists of 2224 amino acids inclusive of a 28-amino acid leader peptide (1). During coagulation, it is converted to the active cofactor FVa via limited proteolysis by thrombin and is spliced into a heavy chain (110 kDa) and a light chain (73 kDa) held together non-covalently by calcium (2). In the presence of a calcium ion and the phospholipid on cell surfaces, FVa and FXa form the prothrombinase complex, which catalyzes the hydrolysis of prothrombin to thrombin (3). Then thrombin cleaves fibrinogen to fibrin, which polymerizes to form a clot. FVa is readily inactivated by anticoagulant activated protein C (4). FV Leiden, a single amino acid mutation, renders FVa resistant to cleavage by activated protein C. It, therefore, over-produces thrombin and leads to excess clotting and hereditary thrombophilia disorder (5). Severe FV deficiency is associated with mild to severe bleeding diathesis (6).

Principle of the Assay

The AssayMax[™] Human Factor V ELISA (Enzyme-Linked Immunosorbent Assay) Kit is designed for detection of factor V in human **plasma, milk, urine, CSF, and cell culture samples**. This assay employs a quantitative **sandwich enzyme immunoassay** technique that measures human factor V in less than 4 hours. A polyclonal antibody specific for human factor V has been pre-coated onto a 96-well microplate with removable strips. Factor V in standards and samples is sandwiched by the immobilized antibody and a biotinylated polyclonal antibody specific for human factor V, which is recognized by a streptavidinperoxidase (SP) conjugate. All unbound material is washed away and a peroxidase enzyme substrate is added. The color development is stopped and the intensity of the color is measured.

Caution and Warning

- This product is for **Research Use Only** and is not intended for use in diagnostic procedures.
- Prepare all reagents (diluent buffer, wash buffer, standard, biotinylated antibody, and SP conjugate) as instructed, prior to running the assay.

- Prepare all samples prior to running the assay. The dilution factors for the samples are suggested in this insert. However, the user should determine the optimal dilution factor.
- Spin down the SP conjugate vial and the biotinylated antibody vial before opening and using contents.
- The Stop Solution is an acidic solution.
- The kit should not be used beyond the expiration date.

Reagents

- Human Factor V Microplate: A 96-well polystyrene microplate (12 strips of 8 wells) coated with a polyclonal antibody against human factor V.
- Sealing Tapes: Each kit contains 3 precut, pressure sensitive sealing tapes that can be cut to fit the format of the individual assay.
- Human Factor V Standard: Human factor V in a buffered protein base (432 ng, lyophilized).
- **Biotinylated Human Factor V Antibody (50x):** A 50-fold concentrated biotinylated polyclonal antibody against human factor V (120 µl).
- EIA Diluent Concentrate (10x): A 10-fold concentrated buffered protein base (30 ml).
- Wash Buffer Concentrate (20x): A 20-fold concentrated buffered surfactant (30 ml, 2 bottles).
- SP Conjugate (100x): A 100-fold concentrate (80 µl).
- **Chromogen Substrate (1x):** A stabilized peroxidase chromogen substrate tetramethylbenzidine (8 ml).
- Stop Solution (1x): A 0.5 N hydrochloric acid solution to stop the chromogen substrate reaction (12 ml).

Storage Condition

- Upon arrival, immediately store components of the kit at recommended temperatures up to the expiration date.
- Store SP Conjugate and Biotinylated Antibody at -20°C.
- Store Microplate, Diluent Concentrate (10x), Wash Buffer, Stop Solution, and Chromogen Substrate at 2-8°C.
- Unused microplate wells may be returned to the foil pouch with the desiccant packs and resealed. May be stored for up to 30 days in a vacuum desiccator.
- Store Standard at 2-8°C before reconstituting with Diluent and at -20°C after reconstituting with Diluent.

Other Supplies Required

- Microplate reader capable of measuring absorbance at 450 nm
- Pipettes (1-20 μl, 20-200 μl, 200-1000 μl, and multiple channel)
- Deionized or distilled reagent grade water

Sample Collection, Preparation, and Storage

- **Plasma:** Collect plasma using one-tenth volume of 0.1 M sodium citrate as an anticoagulant. Centrifuge samples at 3000 x g for 10 minutes and collect plasma. An 800-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles (EDTA or Heparin can also be used as an anticoagulant).
- Milk: Collect milk using sample tube. Centrifuge samples at 800 x g for 10 minutes. A 2-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- Urine: Collect urine using sample pot. Centrifuge samples at 800 x g for 10 minutes. A 2-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -20°C or below for up to 3 months. Avoid repeated freeze-thaw cycles.
- **CSF:** Collect cerebrospinal fluid (CSF) using sample pot. Centrifuge samples at 3000 x g for 10 minutes. A 2-fold sample dilution is suggested into EIA Diluent; however, user should determine optimal dilution factor depending on application needs. The undiluted samples can be stored at -80°C for up to 3 months. Avoid repeated freeze-thaw cycles.
- Cell Culture Supernatant: Centrifuge cell culture media at 1500 rpm for 10 minutes at 4°C to remove debris and collect supernatant. Samples can be stored at -80°C. Avoid repeated freeze-thaw cycles.

Applicable samples may also include biofluids, cell culture, and tissue homogenates. If necessary, user should determine optimal dilution factor depending on application needs.

Refer to Dilution Guidelines for further instruction.

	Guidelines for Dilutions of 100-fold or Greater (for reference only; please follow the insert for specific dilution suggested)					
	100x		10000x			
 A) 4 μl sample: 396 μl buffer (100x) = 100-fold dilution Assuming the needed volume is less than or equal to 400 μl. 			4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) = 10000-fold dilution Assuming the needed volume is less than or equal to 400 μl.			
	1000x		100000x			
A) B)	4 μl sample : 396 μl buffer (100x) 24 μl of A : 216 μl buffer (10x) = 1000-fold dilution Assuming the needed volume is less than or equal to 240 μl.	A) B) C)	4 μl sample : 396 μl buffer (100x) 4 μl of A : 396 μl buffer (100x) 24 μl of B : 216 μl buffer (10x) = 100000-fold dilution Assuming the needed volume is less than or equal to 240 μl.			

Reagent Preparation

- Freshly dilute all reagents and bring all reagents to room temperature before use.
- EIA Diluent Concentrate (10x): If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute EIA Diluent Concentrate 10-fold with reagent grade water to produce a 1x solution. Store for up to 30 days at 2-8°C.
- Human Factor V Standard: Reconstitute the Human Factor V Standard (432 ng) with 0.9 ml of EIA Diluent to generate a 480 ng/ml standard stock solution. Allow the vial to sit for 10 minutes with gentle agitation prior to making dilutions. Prepare duplicate or triplicate standard points by serially diluting from the standard stock solution (480 ng/ml) 4-fold with EIA Diluent to produce 120, 30, 7.5, and 1.875 ng/ml solutions. EIA Diluent serves as the zero standard (0 ng/ml). Any remaining stock solution should be stored at -20°C and used within 30 days. Avoid repeated freeze-thaw cycles.

Standard Point	Dilution	[FV] (ng/ml)
P1	1 part Standard (480 ng/ml)	480
P2	1 part P1 + 3 parts EIA Diluent	120
P3	1 part P2 + 3 parts EIA Diluent	30
P4	1 part P3 + 3 parts EIA Diluent	7.5
P5	1 part P4 + 3 parts EIA Diluent	1.875
P6	EIA Diluent	0.0

- Biotinylated Human Factor V Antibody (50x): Spin down the antibody briefly and dilute the desired amount of the antibody 50-fold with EIA Diluent to produce a 1x solution. The undiluted antibody should be stored at -20°C.
- Wash Buffer Concentrate (20x): If crystals have formed in the concentrate, mix gently until the crystals have completely dissolved. Dilute Wash Buffer Concentrate 20-fold with reagent grade water to produce a 1x solution.
- **SP Conjugate (100x):** Spin down the SP Conjugate briefly and dilute the desired amount of the conjugate 100-fold with EIA Diluent to produce a 1x solution. The undiluted conjugate should be stored at -20°C.

Assay Procedure

- Prepare all reagents, standard solutions, and samples as instructed. Bring all reagents to room temperature before use. The assay is performed at room temperature (20-25°C).
- Remove excess microplate strips from the plate frame and return them immediately to the foil pouch with desiccants inside. Reseal the pouch securely to minimize exposure to water vapor and store in a vacuum desiccator.
- Add 50 μl of Human Factor V Standard or sample to each well. Gentlytap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 2 hours. Start the timer after the last addition.
- Wash five times with 200 µl of Wash Buffer manually. Invert the plate each time and decant the contents; hit 4-5 times on absorbent material to completely remove the liquid. If using a machine, wash six times with 300 µl of Wash Buffer and then invert the plate, decanting the contents; hit 4-5 times on absorbent material to completely remove the liquid.
- Add 50 µl of Biotinylated Human Factor V Antibody to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 1 hour.
- Wash the microplate as described above.
- Add 50 µl of SP Conjugate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Cover wells with a sealing tape and incubate for 30 minutes. Turn on the microplate reader and set up the program in advance.
- Wash the microplate as described above.
- Add 50 µl of Chromogen Substrate to each well. Gently tap plate to thoroughly coat the wells. Break any bubbles that may have formed. Incubate for 10 minutes or until the optimal blue color density develops.
- Add 50 µl of Stop Solution to each well. The color will change from blue to yellow. Gently tap plate to ensure thorough mixing. Break any bubbles that may have formed.

 Read the absorbance on a microplate reader at a wavelength of 450 nm immediately. If wavelength correction is available, subtract readings at 570 nm from those at 450 nm to correct optical imperfections. Otherwise, read the plate at 450 nm only. Please note that some unstable black particles may be generated at high concentration points after stopping the reaction for about 10 minutes, which will reduce the readings.

Data Analysis

- Calculate the mean value of the duplicate or triplicate readings for each standard and sample.
- To generate a standard curve, plot the graph using the standard concentrations on the x-axis and the corresponding mean 450 nm absorbance (OD) on the y-axis. The best fit line can be determined by regression analysis using log-log or four-parameter logistic curve fit.
- Determine the unknown sample concentration from the Standard Curve and multiply the value by the dilution factor.


Typical Data

• The typical data is provided for reference only. Individual laboratory means may vary from the values listed. Variations between laboratories may be caused by technique differences.

Standard Point	ng/ml	OD	Average OD
P1	P1 480		1.503
P2	P2 120		1.229
Р3	P3 30		0.781
P4 7.5		0.463 0.456	0.460
P5 1.875		0.299 0.289	0.294
P6	0.0	0.196 0.194	0.195
	oled Normal Plasma (800x)	0.504 0.499	0.502

Standard Curve

• The curve is provided for illustration only. A standard curve should be generated each time the assay is performed.



Human Factor V Standard Curve

Performance Characteristics

- The minimum detectable dose of human factor V as calculated by 2SD from the mean of a zero standard was established to be 1.3 ng/ml.
- Intra-assay precision was determined by testing three plasma samples twenty times in one assay.
- Inter-assay precision was determined by testing three plasma samples in twenty assays.

	Intra-Assay Precision			Inter-Assay Precision		
Sample	1	2	3	1	2	3
n	20	20	20	20	20	20
CV (%)	4.3%	4.3%	4.5%	9.5%	10.1%	9.9%
Average CV (%)	4.4%				9.8%	

Spiking Recovery

• Recovery was determined by spiking two plasma samples with different factor V concentrations.

Sample	Unspiked Sample (ng/ml)	Spiked Sample (ng/ml)	Expected	Observed	Recovery (%)
	1 5.2	2.5	7.7	8.1	105%
1		5.0	10.2	10.3	101%
		10.0	15.2	14.9	98%
	2 2.4	2.5	4.9	5.4	110%
2		5.0	7.4	7.5	101%
	2.4	10.0	12.4	11.9	96%
Average Recovery (%)					102%

Linearity

• Plasma samples were serially diluted to test for linearity.

Average Percentage of Expected Value (%)			
Sample Dilution	Plasma		
400x	94%		
800x	99%		
1600x	107%		

Cross-Reactivity

Species	Cross-Reactivity (%)
Canine	None
Bovine	None
Monkey	<15%
Mouse	None
Rat	None
Swine	<15%
Rabbit	None

• No significant cross-reactivity observed with factor I (fibrinogen), factor II (prothrombin), factor III (tissue factor), factor VII, factor IX, factor X, factor XI, factor XII, and factor XIII.

Troubleshooting

Causes	Course of Action
Use of expired	 Check the expiration date listed before use.
components	 Do not interchange components from different lots.
Improper wash step	 Check that the correct wash buffer is being used. Check that all wells are empty after aspiration. Check that the microplate washer is dispensing properly. If washing by pipette, check for proper pipetting technique.
Splashing of reagents while loading wells	Pipette properly in a controlled and careful manner.
Inconsistent volumes loaded into wells	 Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
Insufficient mixing of reagent dilutions	 Thoroughly agitate the lyophilized components after reconstitution. Thoroughly mix dilutions.
Improperly sealed microplate	 Check the microplate pouch for proper sealing. Check that the microplate pouch has no punctures. Check that three desiccants are inside the microplate pouch prior to sealing.
Microplate was left unattended between steps	 Each step of the procedure should beperformed uninterrupted.
Omission of step	• Consult the provided procedure for complete list of steps.
Steps performed in incorrect order	Consult the provided procedure for the correct order.
Insufficient amount of reagents added to wells	Check pipette calibration.Check pipette for proper performance.
Wash step was skipped	 Consult the provided procedure for all wash steps.
Improper wash buffer	 Check that the correct wash buffer is being used.
Improper reagent preparation	 Consult reagent preparation section for the correct dilutions of all reagents.
Insufficient or prolonged incubation periods	• Consult the provided procedure for correct incubation time.
Non-optimal sample dilution	 Sandwich ELISA: If samples generate OD valueshigher than the highest standard point (P1), dilute samples further and repeat the assay. Competitive ELISA: If samples generate OD values lower than the highest standard point (P1), dilute samples further and repeat the assay. User should determine the optimal dilution factor for samples.
Contamination of	• A new tip must be used for each addition of different
reagents	samples or reagents during the assay procedure.
	 Verify that the sealing film is firmly in place before placing the assay in the insubator or at room tomporature
Improper pipetting	 the assay in the incubator or at room temperature. Pipette properly in a controlled and careful manner. Check pipette calibration. Check pipette for proper performance.
	Use of expired components Improper wash step Splashing of reagents while loading wells Inconsistent volumes loaded into wells Insufficient mixing of reagent dilutions Improperly sealed microplate was left unattended between steps Omission of step Steps performed in incorrect order Insufficient amount of reagents added to wells Wash step was skipped Improper wash buffer Improper reagent preparation Insufficient or prolonged incubation periods Non-optimal sample dilution Contamination of reagents Contents of wells evaporate

Insufficient mixin reagent dilutio	reconstitution
---------------------------------------	----------------

References

(1) Jenny RJ et al. (1987) Proc Natl Acad Sci USA. 84:4846-

4850. (2) Esmon CT. (1979) J Biol Chem. 254:964-973.

- (3) Nesheim ME et al. (1981) J Biol Chem. 256:6537-6540.
- (4) Kisiel W et al. (1977) Biochemistry. 16:5824-5831.
- (5) Bertina RM *et al.* (1994) *Nature.* 369:64-67.
- (6) Asselta R et al. (2006) J Thromb Haemost. 4(1):26-34.

Version 2.0